Protagenic Therapeutics, Inc.
149 Fifth Avenue
New York, NY 10010
September 14, 2021
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
| Re: | Protagenic Therapeutics, Inc. Registration Statement on Form S-3/A Filed September 10, 2021 File No. 333-258825 |
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933 and on behalf of Protagenic Therapeutics, Inc. (the “Company”), the undersigned hereby requests that the Company’s Registration Statement on Form S-3/A (File No. 333-258825) filed with the U.S. Securities and Exchange Commission (the “Commission”) on September 10, 2021 (the “Registration Statement”), be declared effective on September 17, 2021, at 8:00 a.m., Eastern Standard Time, or as soon as practicable thereafter.
| Very truly yours, | ||
| PROTAGENIC THERAPEUTICS, INC. | ||
| By: | /s/ Alexander K. Arrow | |
Alexander K. Arrow Chief Financial Officer | ||
| cc: | Dean Colucci, Duane Morris LLP |
